Skip to content
Screener

PTC Therapeutics PTCT Business Segments — Net Income Loss

Similar metrics at other companies

U-Haul Holding logo
UHALLife Insurance — Net Income Loss
$2.69M+29.2%
United States Lime & Minerals, Inc. logo
USLMLime And Limestone Operations — Net Income Loss
$30.58M-10.4%
NewAmsterdam Pharma Company logo
NAMSNet Income Loss
-$64.14M-269%
Orthofix Medical Inc. logo
OFIXNet Income Loss
-$15.8M-12.2%
Taboola.com Ltd. logo
TBLANet Income Loss
$4.32M+199%
United Therapeutics logo
UTHRNet Income Loss
$333M+7.6%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other income (expense), net1,609(6,305)
(Loss) income before income tax expense(2,462)929,828
Income tax expense(347)(63,266)
Net (loss) income attributable to common stockholders$(2,809)$866,562
Weighted-average shares outstanding:
Basic (in shares)82,521,02378,115,836
Diluted (in shares)82,521,02386,385,922
Net (loss) income per share—basic (in dollars per share)$(0.03)$11.09

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's business segments — net income loss?
PTC Therapeutics (PTCT) reported business segments — net income loss of -$2.81M in Q1 2026.
How has PTC Therapeutics's business segments — net income loss changed year-over-year?
PTC Therapeutics's business segments — net income loss decreased by 100.3% year-over-year, from $866.56M to -$2.81M.
What is the long-term trend for PTC Therapeutics's business segments — net income loss?
Over 2 years (2022 to 2024), PTC Therapeutics's business segments — net income loss has grown at a -19.4% compound annual growth rate (CAGR), from -$559.02M to -$363.3M.
What does business segments — net income loss mean?
This represents the final bottom-line profitability of the life science segment after accounting for all revenues, operating expenses, and segment-specific allocations. It is the definitive measure of the segment's financial viability and contribution to the overall corporate bottom line.

Ask your AI about PTC Therapeutics's business segments — net income loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude